Introduction and Objective: Metformin taken during pregnancy crosses the placenta. In vitro, it has robust metabolic stress effects in fetal hepatocytes. We hypothesized that metformin exposure in utero would disrupt oxidative metabolism and produce hepatocellular injury in the fetal liver, a major site of uptake.Methods: Pregnant Rhesus macaques received vehicle (VEH), or metformin (MET) and […]
Read MoreAuthor: sugaradmin
1304-OR: Diabetes Community Health Worker Improves Glycemic Control for Complex Patients in Urban Enhanced Primary Care Model
Introduction and Objective: Despite benefits of modern diabetes (DM) care, population-level glycemic control has not improved, especially among groups often marginalized from traditional care due to socioeconomic and cultural factors.Methods: The DICHA (DM In Control for Hispanics through an Alliance) program is a 6-month enhanced primary care model for Latino people with diabetes (LPWD) that […]
Read More
What Is the ‘New’ FDA Approved Sunscreen Ingredient?
Share on PinterestBemotrizinol (PARSOL Shield), an advanced sunscreen filter that has long been used in Europe and Asia, has been approved for use in the U.S. by the FDA. Image Credit: Photo by LumiNola/Getty Images The FDA has approved bemotrizinol (PARSOL Shield). This is the first new sunscreen ingredient approved in over 20 years, offering […]
Read More1313-OR: Harmine Engages Two Distinct Signaling Pathways in Human β-Cells: DYRK1A-Driven Proliferation and PKA-Mediated Differentiation and Function
Introduction and Objective: Small-molecule DYRK1A inhibitors such as harmine stimulate adult human β-cell proliferation; however, only a subset enhances β-cell identity/function. We sought to define the signaling mechanism underlying this phenotype, determine whether it is a class effect or requires DYRK1A inhibition, and identify the responsible pathway in human β-cells.Methods: Primary human islets and R7T1 […]
Read More1294-OR: Efruxifermin Improved Liver Disease and Insulin Sensitivity in Participants with Type 2 Diabetes and Metabolic Dysfunction–Associated Steatohepatitis (MASH) Cirrhosis in the SYMMETRY Trial
Introduction and Objective: T2D increases the risk of clinical outcomes in MASH cirrhosis. This post hoc analysis assessed changes in liver disease and insulin sensitivity in participants with baseline T2D and compensated cirrhosis due to MASH in the SYMMETRY trial of efruxifermin.Methods: SYMMETRY (NCT05039450) is a phase 2b, randomized, placebo-controlled trial that evaluated efruxifermin QW […]
Read More1287-OR: Dyadic Coping and Data Sharing among Older Adults with Type 1 Diabetes: A Qualitative Analysis of the Share Plus Intervention
Introduction and Objective: Older adults with type 1 diabetes face age-related changes. Dyadic coping, where care partners (CPs) and people with diabetes (PWD) collaboratively manage diabetes, can improve outcomes but is hindered by misaligned illness appraisals (viewing diabetes as individual vs. shared responsibility) and communication difficulties. This study describes experiences of older PWD/CP dyads in […]
Read More1281-OR: Risk of Myocardial Infarction (MI) and Ischemic Stroke (IS) following Herpes Zoster (HZ) in Older Adults with T2DM in the U.S.
Introduction and Objective: HZ has been associated with a higher risk of cardiovascular events, but evidence in T2DM is limited. This analysis assessed associations between HZ and MI/IS in older adults with T2DM.Methods: Using US administrative claims and EHR data (Optum Market Clarity, 2016-2024), adults with T2DM and HZ were identified by ICD-10 diagnosis codes. […]
Read MoreFactors associated with hypoglycemic or hyperglycemic events during Ramadan among persons with diabetes in Qatar
Background Despite the high prevalence of diabetes in Qatar, Ramadan-related glycemic events remain inadequately characterized. This study examined sociodemographic, clinical and behavioral factors independently associated with hypoglycemic or hyperglycemic events among patients with diabetes during Ramadan in Qatar. Methods A retrospective analysis was conducted using routinely collected data from the Qatar Diabetes Association (QDA) Ramadan […]
Read More1318-OR: CNTY-813: Scalable Production of Allo-Evasion 5.0-Engineered IPSC Beta Islets for Off-the-Shelf Cell Therapies
Introduction and Objective: Type 1 diabetes cell therapies aim to restore normoglycemia by replacing lost beta cells, but low clinical supply and the need for chronic immune suppression are key challenges. CNTY-813 overcomes these challenges via clinical-scale production of Allo-Evasion™ 5.0-engineered iPSC-derived beta islets that are engineered for immune evasion. Thus, CNTY-813 provides an off-the-shelf, […]
Read More1343-OR: Continuous Glucose Monitoring vs. Blood Glucose Monitoring in Patients with Type 2 Diabetes Managed on Insulin in Primary Care: The GluCoCare Study
Introduction and Objective: We evaluated the effectiveness of CGM versus BGM in the pragmatic management of T2D on insulin in primary care, in a large randomized controlled trial in the upper Midwest.Methods: This two-arm trial was cluster-randomized based on primary care clinic attendance: (BGM 25 clinics) or CGM (25 clinics). We recruited 360 adults with […]
Read More